These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 29232714)

  • 1. Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients.
    Lee H; Park KH; Ryu JH; Choi AR; Yu JH; Lim J; Han K; Kim SI; Yang CW; Chung BH; Oh EJ
    PLoS One; 2017; 12(12):e0189488. PubMed ID: 29232714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study.
    Banas B; Steubl D; Renders L; Chittka D; Banas MC; Wekerle T; Koch M; Witzke O; Mühlfeld A; Sommerer C; Habicht A; Hugo C; Hünig T; Lindemann M; Schmidt T; Rascle A; Barabas S; Deml L; Wagner R; Krämer BK; Krüger B
    Transpl Int; 2018 Apr; 31(4):436-450. PubMed ID: 29284181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.
    Abate D; Saldan A; Mengoli C; Fiscon M; Silvestre C; Fallico L; Peracchi M; Furian L; Cusinato R; Bonfante L; Rossi B; Marchini F; Sgarabotto D; Rigotti P; Palù G
    J Clin Microbiol; 2013 Aug; 51(8):2501-7. PubMed ID: 23678073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
    BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.
    Gliga S; Korth J; Krawczyk A; Wilde B; Horn PA; Witzke O; Lindemann M; Fiedler M
    J Clin Virol; 2018 Aug; 105():91-96. PubMed ID: 29936407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients.
    Banas B; Böger CA; Lückhoff G; Krüger B; Barabas S; Batzilla J; Schemmerer M; Köstler J; Bendfeldt H; Rascle A; Wagner R; Deml L; Leicht J; Krämer BK
    BMC Immunol; 2017 Mar; 18(1):15. PubMed ID: 28270092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early cytomegalovirus-specific T-cell response and estimated glomerular filtration rate identify patients at high risk of infection after renal transplantation.
    Leone F; Gigliotti P; Mauro MV; Lofaro D; Greco F; Tenuta R; Perugini D; Papalia T; Mollica A; Perri A; Vizza D; La Russa A; Toteda G; Lupinacci S; Giraldi C; Bonofiglio R
    Transpl Infect Dis; 2016 Apr; 18(2):191-201. PubMed ID: 26878346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
    Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK
    Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
    Chiereghin A; Potena L; Borgese L; Gibertoni D; Squarzoni D; Turello G; Petrisli E; Piccirilli G; Gabrielli L; Grigioni F; Lazzarotto T
    J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29305542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
    J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic usefulness of the cytomegalovirus (CMV)-specific T cell-based assay for predicting CMV infection after kidney transplant.
    Kim T; Lee HJ; Kim SM; Jung JH; Shin S; Kim YH; Sung H; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
    Korean J Intern Med; 2020 Mar; 35(2):438-448. PubMed ID: 29865778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.
    Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P
    Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-transplant assessment of CMV-specific immune response by Elispot assay in kidney transplant recipients.
    Rittà M; Costa C; Sidoti F; Ballocco C; Ranghino A; Messina M; Biancone L; Cavallo R
    New Microbiol; 2015 Jul; 38(3):329-35. PubMed ID: 26147141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMV-specific Cell-mediated Immunity at 3-month Prophylaxis Withdrawal Discriminates D+/R+ Kidney Transplants at Risk of Late-onset CMV Infection Regardless the Type of Induction Therapy.
    Jarque M; Melilli E; Crespo E; Manonelles A; Montero N; Torras J; Cruzado JM; Luque S; Gil-Vernet S; Grinyó JM; Bestard O
    Transplantation; 2018 Nov; 102(11):e472-e480. PubMed ID: 30130330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.
    Barabas S; Spindler T; Kiener R; Tonar C; Lugner T; Batzilla J; Bendfeldt H; Rascle A; Asbach B; Wagner R; Deml L
    BMC Immunol; 2017 Mar; 18(1):14. PubMed ID: 28270111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of interferon gamma ELISPOT assay to detect human cytomegalovirus specific T-cell responses in solid organ transplants.
    Abate D; Saldan A; Forner G; Tinto D; Bianchin A; Palù G
    J Virol Methods; 2014 Feb; 196():157-62. PubMed ID: 24216234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment.
    Fernández-Ruiz M; Giménez E; Vinuesa V; Ruiz-Merlo T; Parra P; Amat P; Montejo M; Paez-Vega A; Cantisán S; Torre-Cisneros J; Fortún J; Andrés A; San Juan R; López-Medrano F; Navarro D; Aguado JM;
    Clin Microbiol Infect; 2019 Mar; 25(3):381.e1-381.e10. PubMed ID: 29803844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
    Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normalizing ELISPOT responses to T-cell counts: a novel approach for quantification of HCMV-specific CD4(+) and CD8(+) T-cell responses in kidney transplant recipients.
    Calarota SA; Chiesa A; Scaramuzzi L; Adzasehoun KM; Comolli G; Mangione F; Esposito P; Baldanti F
    J Clin Virol; 2014 Sep; 61(1):65-73. PubMed ID: 24961915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection.
    Tormo N; Solano C; Benet I; Nieto J; de la Cámara R; Garcia-Noblejas A; Clari MA; Chilet M; López J; Hernández-Boluda JC; Remigia MJ; Navarro D
    J Med Virol; 2010 Jul; 82(7):1208-15. PubMed ID: 20513086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.